Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A

J Hepatol. 2015 Sep;63(3):554-63. doi: 10.1016/j.jhep.2015.03.033. Epub 2015 Apr 4.

Abstract

Background & aims: Single nucleotide polymorphisms within the interferon lambda 4 (IFNL4) locus are strongly associated with spontaneous clearance of hepatitis C virus (HCV) infection and early viral response to interferon therapy. Interaction between host genotype and amino acid substitutions might also influence the risk of antiviral resistance in interferon-free direct acting antiviral (DAA) therapies.

Methods: The relationship between IFNL4 genotype and HCV substitutions was analyzed in 929 patients with chronic HCV genotype 1b infection. Ultra-deep sequencing and quasispecies reconstruction was performed on the N-terminal region of NS5A in 57 patients.

Results: IFNL4 genotype was strongly associated with HCV NS5A Y93 and core protein substitutions, and the number and diversity of predicted quasispecies was marginally greater in IFNL4 TT/TT patients compared to TT/ΔG, ΔG/ΔG patients. RNA secondary structure prediction of the NS5A region suggests that variable sites are more likely to occupy unpaired, high entropy positions.

Conclusions: HCV infection is proposed to induce a more efficient antiviral response in individuals with the IFNL4 TT/TT genotype that results either in viral clearance or selection for viral adaptations. The association between IFNL4 TT/TT genotype and Y93 substitutions may impact the risk of antiviral resistance in NS5A inhibitors in DAA therapy.

Keywords: Antiviral resistance; Daclatasvir; Direct acting antivirals; HCV core protein; ISDR; Interferon lambda 4; NS5A; Next generation sequencing; Positive selection; Quasispecies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Child
  • Child, Preschool
  • Drug Resistance, Viral
  • Female
  • Genetic Loci
  • Genotype
  • Hepatitis C / drug therapy*
  • Humans
  • Interleukins / genetics*
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • RNA, Viral / chemistry
  • Viral Nonstructural Proteins / genetics*

Substances

  • IFNL4 protein, human
  • Interleukins
  • RNA, Viral
  • Viral Nonstructural Proteins
  • NS-5 protein, hepatitis C virus